Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.58

-3.7%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

At a Glance

Live Snapshot
Market Cap$327.86M
EPS-0.4700
P/E Ratio-5.49
Earnings Date08/04/2026

naut

Account Payables

Last Annual Value

943.00K

3-Year CAGR

-9%

5-Year CAGR

15%

10-Year CAGR

%

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Competitors Analysis of Account Payables

NAUT · NASDAQ
CompanyAccount Payables
CAGR 3Y
CAGR 5Y
CAGR 10Y
943.00K
-16.8%-11.4%N/A 
3.58M
-14.0%-19.7%N/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
0.00
N/AN/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
5.40M
-5.9%20.9%N/A
4.24M
-7.1%-15.9%2.4%
1.31M
91.6%11.5%N/A
1.54M
-9.9%2.0%N/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
82.99M
10.5%22.2%31.4%
1.12M
-32.8%-23.1%N/A
2.53M
2.1%6.8%N/A
0.00
N/AN/AN/A
Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Fair Value Envelope

NAUT · NASDAQ

Our analysis suggests that NAUT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.58, this represents a potential HIDDEN relative to our calculated worth for Nautilus Biotechnology, Inc..

Intrinsic Value
Current Price: $2.58